What Pathnostics does

Pathnostics is a precision diagnostics company founded in 2011 and headquartered in Irvine, California, operating a CAP-accredited, CLIA-certified laboratory network across California, Florida, and Michigan. The company specializes in urology and infectious disease diagnostics, with its flagship Guidance platform combining multiplex PCR molecular detection (identifying 26 organisms, 3 bacterial groups, and 32 resistance genes) with proprietary Pooled Antibiotic Susceptibility Testing (P-AST) that evaluates antibiotic effectiveness against the entire pool of organisms in a patient specimen. This approach is designed to capture polymicrobial interactions that standard culture-based methods miss, with results delivered in 24-36 hours versus 3-5 days for conventional culture.

The company's primary commercial products are Guidance UTI with P-AST and Guidance Prostatitis, targeting complicated, recurrent, and persistent urinary tract infections. The broader menu includes anatomic pathology, Barrett's Esophagus testing, Bladder FISH/UroVysion, cytology and high-risk HPV testing, and an at-home specimen collection program called Guidance @Home. Pathnostics is a portfolio company of Water Street Healthcare Partners and operates as a private, PE-backed clinical laboratory.

The business model is B2B and transaction-fee based: healthcare providers (urologists, primary care physicians, OBGYNs, and health systems) order tests, specimens are processed at Pathnostics laboratories, and the company bills insurance payors and patients under standard laboratory CPT codes. Distribution occurs through direct enterprise field sales, a dedicated in-house Customer Care team, active presence at urology and infectious disease conferences (AUA, ISPOR, AUGS, PFD Week), and a channel partnership with Marathon Medical extending access to the VA/DoD market. The company reports more than 2,000 providers ordering monthly, has accumulated a repository of over 300,000 UTI cases, and has supported 8 clinical studies and 15+ peer-reviewed publications underlying its clinical evidence base.

Name

Pathnostics

Legal name

Pathnostics

Website

https://pathnostics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

101–250 employees

Short description

Pathnostics is a PE-backed clinical laboratory operating CAP/CLIA-certified facilities in California, Florida, and Michigan. It serves urologists, primary care physicians, and OBGYNs with proprietary multiplex PCR plus P-AST diagnostic tests for complicated, recurrent, and persistent urinary tract infections.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

• Clinical diagnostic testing
• Molecular pathology services
• Infectious disease diagnostics
• Antibiotic susceptibility testing
• Urology diagnostic services

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Laboratory Diagnostic Testing Services: Pathnostics operates CAP-accredited and CLIA-certified laboratories providing clinical diagnostic testing services. Healthcare providers order tests (primarily Guidance UTI and Guidance Prostatitis) and send specimens to Pathnostics laboratories for analysis. The company bills insurance payors and potentially patients directly for testing services.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Pathnostics operates CAP-accredited, CLIA-certified clinical laboratories that provide precision diagnostic testing services, with its flagship Guidance® UTI with P-AST™ test combining multiplex PCR molecular detection (identifying 26 organisms, 3 bacterial groups, and 32 resistance genes) with proprietary Pooled Antibiotic Susceptibility Testing (P-AST™) that evaluates antibiotic effectiveness against the entire infection including polymicrobial interactions. The company delivers results in 24-36 hours and serves urologists, primary care physicians, OBGYNs, and other healthcare providers managing complicated, recurrent, and persistent UTIs, prostatitis, and related conditions.

Product overview

Pathnostics offers a diagnostic platform centered on its Guidance brand of precision diagnostic tests. The core platform combines multiplex PCR (M-PCR) molecular detection with proprietary pooled antibiotic susceptibility testing (P-AST) technology. The main products include Guidance UTI with P-AST (flagship test for complicated/recurrent UTIs) and Guidance Prostatitis, both utilizing the same dual M-PCR + P-AST approach. Additional diagnostic services include Anatomic Pathology (cancer diagnostics), Barrett's Esophagus testing, Gyn Cytology High Risk Test, Bladder FISH/UroVysion, and Cytology/High Risk HPV testing. The company also offers Guidance @Home for at-home specimen collection and comprehensive Urinalysis testing. All products operate under the CAP-accredited and CLIA-certified laboratory network with facilities in California, Florida, and Michigan.

Differentiator

Problem solved

Functional benefit

Brands

• Guidance UTI: Advanced precision diagnostic test for complicated, recurrent, or persistent UTIs combining PCR and Pooled Antibiotic Susceptibility Testing (P-AST™).
• Guidance Prostatitis
• P-AST™
• Guidance @Home

Products and services

• Guidance UTI with P-AST Flagship precision diagnostic test for complicated, recurrent, or persistent urinary tract infections. Combines multiplex PCR (M-PCR) molecular detection (identifying 26 individual organisms and 3 bacterial groups, plus 32 resistance genes) with proprietary pooled antibiotic susceptibility testing (P-AST) that evaluates antibiotic effectiveness against the entire infection including polymicrobial interactions. Delivers results in 24-36 hours from lab receipt. The only NYSDOH-approved advanced UTI test combining molecular technology with pooled antibiotic susceptibility results.
• Guidance Prostatitis Advanced diagnostic testing for suspected acute or chronic prostatitis. Uses the same dual approach (PCR + P-AST™) as Guidance UTI, applied to voided post-DRE-massage urine and semen samples. Provides personalized antibiotic susceptibility results accounting for polymicrobial interactions.
• Anatomic Pathology Cancer diagnostic testing services including histopathology and cytology across urology, women's health, and gastroenterology practice areas.
• Barrett's Esophagus Testing Diagnostic testing for Barrett's Esophagus, a condition that can lead to esophageal cancer, supporting gastroenterology practices.
• Gyn Cytology High Risk Test Women's health diagnostic testing for high-risk gynecologic cytology conditions.
• Bladder FISH / UroVysion Fluorescence in situ hybridization (FISH) test for bladder cancer detection and monitoring using the UroVysion assay.
• Cytology / High Risk HPV Cytology testing combined with high-risk human papillomavirus (HPV) screening for cervical cancer risk assessment in women's health.
• Urinalysis Comprehensive urinalysis testing including macroscopic components (color, clarity, specific gravity, pH, protein, glucose, ketones, blood, bilirubin, urobilinogen, nitrite, leukocyte esterase) with automatic reflex to microscopy when defined criteria are positive.
• Guidance @Home At-home specimen collection program extending the same diagnostic testing (Guidance UTI) to patients who cannot provide samples in clinic. Includes simple collection kit with prepaid return logistics and high-touch patient support, maintaining diagnostic quality outside healthcare settings.

Quantifiable outcome

• 41.3% lower composite outcome event rate (inpatient, urgent care, ER, SNF) compared to standard urine culture
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• DispatchHealthcoreStrategic or Co-development Partner · 28 September 2022Clinical study partnership to evaluate Guidance UTI vs. standard urine culture among 6,800 patients receiving in-home care. DispatchHealth provides access to their home-based high-acuity care model and patient enrollment for the observational study assessing clinical outcomes, healthcare resource utilization, and costs. The partnership represents a unique approach to generating real-world evidence in the home care setting.
• Marathon MedicalcoreChannel Partner/ Reseller/ DistributorOrdering channel partnership enabling veterans and military personnel to access Guidance UTI and Guidance Prostatitis tests through the Department of Defense healthcare system. Marathon Medical serves as the distribution partner for this patient population.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• bioMérieux: Global in vitro diagnostics leader in microbiology, including culture media, AST systems, and molecular platforms. A broad incumbent that competes across Pathnostics' laboratory workflow and could enter the advanced UTI susceptibility space with greater scale.
• Quest Diagnostics: One of the two largest US clinical reference laboratories, offering broad infectious disease and molecular testing. Comparable as the dominant scale player whose UTI menu and payor reach would compete against Pathnostics for routine and complex UTI send-outs.
• Opko Health (BioReference Laboratories): Diversified diagnostics business including BioReference Laboratories, with national specialty and routine testing capacity. Comparable as a national specialty lab operator that could expand molecular UTI panels and compete for urology/OBGYN accounts.
• Laboratory Corporation of America (Labcorp): Largest US clinical reference laboratory with national infrastructure across routine and esoteric diagnostics. Comparable as the principal competitor for hospital and health-system UTI send-out volume and a potential acquirer of advanced UTI diagnostics assets.
• Becton, Dickinson and Company (BD): Major microbiology and diagnostics platform with culture, identification, and AST systems (e.g., BD Phoenix). Comparable as an incumbent whose installed-base AST technology competes with P-AST at the methodology level.

Direct peers

• Accelerate Diagnostics: Developer of rapid phenotypic antimicrobial susceptibility testing platforms for serious infections. Comparable in its emphasis on faster, clinically actionable AST vs. traditional culture — the same differentiation thesis Pathnostics applies to UTIs.
• MicroGen Diagnostics: Specialty molecular diagnostics laboratory focused on urinary tract and other infectious disease pathogens using PCR-based panels. Closest direct competitor to Pathnostics' Guidance UTI in clinical urology and recurrent UTI workflows.

Emerging players

• Aperiomics: Specialty molecular diagnostics company using metagenomic sequencing for complex and hard-to-detect infectious diseases. Comparable as a clinical-lab-delivered infectious disease molecular diagnostic competing for the same complex-case physician relationships.
• T2 Biosystems: Molecular diagnostics company offering rapid direct-from-specimen panels for bloodstream and other infections. Comparable as a specialty molecular infectious disease diagnostics player targeting faster, culture-independent clinical decision-making.

Others

• Copan Diagnostics: Leader in pre-analytic specimen collection and transport systems, including automated urine workflow and eNAT molecular transport. Comparable as an ecosystem enabler — its specimen-handling technology sits alongside Pathnostics' Guidance @Home collection kit.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pathnostics